US-based Agilent Technologies has signed a definitive agreement to acquire privately-owned biotechnology company ACEA Biosciences for $250 million in cash. The acquisition will enable Agilent to widen its growth prospects and further expand the company’s scope in the fast-growing cell analysis market, according to a statement of Agilent. “ACEA represents a unique opportunity for Agilent to expand its team and broaden its portfolio with highly complimentary technology, increasing the relevance and impact we can have with our customers in the cell …

Agilent Technologies Acquires Qiming-backed Biotechnology Firm ACEA Biosciences appeared first on China Money Network.